



- **5 products**
- **260 patients**
- **Issues with adherence, education and symptom management was reviewed**
- **Days on therapy for prostate cancer drugs was reviewed**



- **Follow up education increased tolerance to drugs**
- **30 day follow up visits after drug initiation increased adherence and days on therapy**
- **Number of unnecessary patient visits reduced considerably**



- **Issues with copay's authorization education and side effects were found to be the main reasons of stopping therapy**
- **Patients were able to be titrated better with real time interventions and support**
- **Patients were more engaged with their treatment and were happy to have someone take extra care for them.**



SPAC

Sargas Pharmaceutical Adherence and
Compliance International



- **Prostate cancer patients were found to be on therapy for 7.9 months and 5.7 months after initiation from pharmacy**
- **Patients tend to skip their therapy to reduce cost**
- **Second and third fills had gaps and were found to be 3rd to 5th month for second refill and 4th to 7th month for 3rd fill**
- **Vomiting was the number one reason for stopping therapy**



- **Followed by diarrhea and dry skin**
- **In case of prostate cancer clinical trials patients were on therapy for more than double the time then when the drug went commercial**
- **SPAC is the only program that can align the treatments with clinical trials to deliver better outcomes**

Adherence and Compliance Approach

Revenue Potential



Based on missed months of therapy in one case our programs would deliver 50% more time on therapy which would be same as clinical trials

For this the revenue would go up from 1.7 billion to over 3 billion

Our services are lot economical to contract with and we only help deliver more days on therapy, proactive dose management for titration and symptom management to intervene before the dose is completely stopped.